Updates and Insights on the Medical Science of Prostate Cancer

This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Prostate Cancer Basic Facts

Biology of Bone Metastases in Prostate Cancer

Prostate Cancer Cells Induce Bone Remodeling

SREs in Prostate Cancer

Selected Bone-Targeted Therapies in mCRPC

Comparison of Antiresorptive Therapies for Bone Metastases

Denosumab vs Zoledronic Acid for Bone Metastases in CRPC

Antiresorptive Therapies Summary

Comparison of FDA-Approved AR Inhibitors

Selecting Abiraterone vs Enzalutamide

Phase 3 Trials of Abiraterone and Enzalutamide in Chemotherapy-Naive mCRPC

ODM-201 (Darolutamide) A Novel AR Inhibitor

ARADES Phase 1/2 Study of ODM-201 in Progressive mCRPC

ARADES Phase 1/2 Study of ODM-201 in Progressive mCRPC—Safety

ARASENS Randomized, Double-Blind, Phase 3 Trial of ODM-201 in Hormone-Sensitive mPC

Ongoing Issues Managing Nonmetastatic CRPC

Phase 3 Trial of Denosumab in Nonmetastatic CRPC

Phase 3 Trial of Denosumab in Nonmetastatic CRPC Results by PSADT

PROSPER Randomized, Double-Blind, Phase 3 Trial of Enzalutamide in Nonmetastatic CRPC

SPARTAN Randomized, Double-Blind, Phase 3 Trial of Apalutamide in Nonmetastatic CRPC

ARAMIS Randomized, Double-Blind, Phase 3 Trial of ODM-201 in High-Risk Nonmetastatic CRPC

Radium-223 A Novel Radioisotope

ALSYMPCA Randomized, Phase 3 Trial of Radium-223 in Symptomatic mCRPC

Phase 3b Expanded Access Trial of Radium-223

ALSYMPCA Subgroup Analysis According to Prior Docetaxel

CA184-043 Phase 3 Trial of Ipilimumab After Docetaxel in mCRPC

Phase 1 Trial of Tremelimumab + Short-Term ADT in PSA-Recurrent Prostate Cancer

Phase 2 Trial of Pembrolizumab in mCRPC Post-Enzalutamide

Phase 2 Study of Olaparib in mCRPC

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)